This review provides an overview of coronary artery disease prevalence, its impact on clinical outcomes, and treatment strategies in patients with severe aortic stenosis requiring SAVR or TAVI.
This review provides an overview of the prevalence, clinical impact, and treatment strategies for patients with coexisting severe aortic stenosis and coronary artery disease.
Coronary artery disease (CAD) and aortic stenosis (AS) share pathophysiological mechanisms and risk factors. Moreover, the prevalence of CAD increases among elderly patients with severe AS since disease progression is strongly associated with age for both CAD and AS. These factors contribute to the frequent coexistence of CAD and AS. Patients with concomitant AS and CAD are characterised by higher baseline risk profiles with a larger number of comorbidities as compared to patients with isolated AS. Therefore, adequate therapeutic strategies are crucial for the treatment of these patients. The number of patients undergoing concomitant coronary artery bypass grafting (CABG) and surgical aortic valve replacement (SAVR) doubled during the last decade. Moreover, the development and rapid integration of transcatheter aortic valve implantation (TAVI) into clinical practice in western European countries has further extended invasive treatment of AS to elderly high-risk patients not considered suitable candidates for SAVR, frequently presenting with CAD. The aim of this review article is to provide an overview on CAD prevalence, impact on clinical outcomes, and treatment strategies in patients with severe AS requiring SAVR or TAVI.
Stefanini et al. (2013) conducted a review in Severe aortic stenosis and coronary artery disease. Surgical aortic valve replacement (SAVR) and transcatheter aortic valve implantation (TAVI) was evaluated. This review provides an overview of coronary artery disease prevalence, its impact on clinical outcomes, and treatment strategies in patients with severe aortic stenosis requiring SAVR or TAVI.